US20110130451A1 - Method of treating dry eye disorders and uveitis - Google Patents

Method of treating dry eye disorders and uveitis Download PDF

Info

Publication number
US20110130451A1
US20110130451A1 US13/022,692 US201113022692A US2011130451A1 US 20110130451 A1 US20110130451 A1 US 20110130451A1 US 201113022692 A US201113022692 A US 201113022692A US 2011130451 A1 US2011130451 A1 US 2011130451A1
Authority
US
United States
Prior art keywords
dry eye
compound
uveitis
formula
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/022,692
Inventor
Peter G. Klimko
Mark R. Hellberg
Daniel A. Gamache
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/127,895 external-priority patent/US20050256189A1/en
Application filed by Alcon Inc filed Critical Alcon Inc
Priority to US13/022,692 priority Critical patent/US20110130451A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ALCON, INC.
Publication of US20110130451A1 publication Critical patent/US20110130451A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Definitions

  • the present invention is directed to the treatment of dry eye disorders.
  • the present invention is directed toward the use of 5,6,7-trihydroxyheptanoic acid and its analogs to treat dry eye and uveitis in mammals.
  • Dry eye also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
  • Practitioners have taken several approaches to the treatment of dry eye.
  • One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day.
  • Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
  • Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils.
  • Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye, Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998).
  • phospholipid compositions for the treatment of dry eye are disclosed in U.S. Pat. Nos. 4,131,651 (Shah et al.), 4,370,325 (Packman), 4,409,205 (Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.) and 5,578,586 (Glonek et al.).
  • U.S. Pat. No. 5,174,988 discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
  • U.S. Pat. No. 5,041,434 discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye conditions in post-menopausal women
  • U.S. Pat. No. 5,290,572 discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production
  • U.S. Pat. No. 4,966,773 discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
  • Uveitis is an intraocular inflammatory condition that is usually limited to the anterior ocular structures, and can be managed with topical corticosteroids.
  • the inflammatory process can extend behind the lens to affect the pars plana, the vitreous cavity, the choroid, and the retina.
  • These intermediate and posterior manifestations are relatively rare but contribute disproportionately to visual morbidity and present serious therapeutic difficulties.
  • Systemic corticosteroids constitute the first line of treatment for most sight-threatening uveitides. Their long term use is limited by universal and debilitating adverse effects.
  • Second-line agents that allow a reduction in steroid use, such as cyclosporin and azathioprine offer alternative approaches. Unfortunately their use is frequently limited by a narrow therapeutic window and significant adverse side effects.
  • Lipoxin A 4 and certain analogs thereof have been reported to be anti-inflammatory agents (see for example Serhan et. aL, U.S. Pat. No. 5,441,951). Certain lipoxin analogs have been claimed for treating dry eye (Gamache et. al., U.S. Pat. No. 6,645,978 B1). However to the best of our knowledge no compounds of the present invention have been described for treating dry eye or uveitis.
  • the present invention is directed to methods for the treatment of dry eye and uveitis.
  • a 5,6,7-trihydroxyheptanoic acid or analog is administered to a patient.
  • the 5,6,7-trihydroxyheptanoic acid or analog is preferably administered in an ophthalmic composition dosed topically to a patient's eye.
  • composition comprising a compound of formula I is topically administered to a mammal in need thereof:
  • Compound 1 is commercially available from Biomol Research Laboratories, Plymouth Meeting, Pa., and compound 2 can be prepared as detailed in Lee et. al., Biochemical and Biophysical Research Communications 1991, 180(3), 1416-21.
  • Compounds 3-6 can be prepared as described in examples 1-4 below.
  • a solution of methyl ester 1 in aqueous MeOH is heated to reflux in the presence of 3 equivalents of lithium hydroxide. After 6 h the reaction is cooled to room temperature and the pH of the solution is adjusted to 6 by the addition of 70-9 mesh sulfonic acid resin MP (commercially available from Novabiochem/EMD Biosciences, 10394 Pacific Center Court, San Diego, Calif. 92121). The solution is filtered through a 0.2 ⁇ M poly-terfluoroethylene syringe filter and concentrated to afford the lithium carboxylate 4 as a white solid.
  • a solution of lactone 3 in THF is treated with 3 to 5 equivalents of an ethanolic solution of sodium ethoxide. After 10 h the reaction is quenched by the addition of saturated aqueous potassiuni dihydrogen phosphate until the pH is about 6. The solution is extracted with ethyl acetate, the organic layer is dried over MgSO 4 , filtered, and concentrated, and the residue is chromatographed on a silica gel column to afford ethyl ester 5.
  • Compound 1 was evaluated in a rabbit model of dry eye.
  • New Zealand white rabbits (approximately 2.5 kg; obtained from Myrtle's Rabbitry, Thompson Station, Tenn.) were randomized and dosed topically twice a day with either 50 ⁇ l of compound 1 formulated in 0.064%/BSS® at concentrations of 1, 10 , or 100 ⁇ M , or with 0.064%/BSS® vehicle.
  • the rabbits were anesthetized by subcutaneous administration of ketamine hydrochloride (30 mg/kg) and xylazine (6 mg/kg) and each rabbit received bilateral injections of Conconavilin A (ConA) (300 ⁇ g/30 ⁇ l) or saline (30 ⁇ l).
  • ConA Conconavilin A
  • Desiccation was initiated one day following lacrimal gland injection by placing conscious animals in an environmental chamber (20-30% humidity, 75° C.). Following 72 hours of exposure to environment, the animals were assessed for corneal staining upon exposure of the cornea to the dye methylene blue; less staining indicates less damage to the cornea.
  • the rabbits were anesthetized by subcutaneous administration of ketamine hydrochloride (30 mg/kg) and xylazine (6 mg/kg). Sutures were placed in each upper and lower eyelid and lifted to form a corneal/conjunctival cup. Methylene blue dye (1 mL, 1% in distilled water) was added to the cup for five minutes and the excess removed by washing with 200 mL of BSS®. The contralateral eye was then stained using the same procedure.
  • Percent inhibition was calculated as ⁇ 1-[(A660 test item -A660 Normal )/(A660 BSS -A660 Normal )] ⁇ 100, where A660 test item is the absorbance of dye from ConA-injected eyes dosed with compound 1, A660 Normal is the absorbance of dye from saline-injected eyes, and A660 BSS is the absorbance of dye in ConA-injected eyes dosed with 0.064% ethanol/BSS® solution vehicle. A higher percent inhibition of staining indicates more protection of the cornea from damage.
  • TBUT tear breakup time
  • % inhibition of corneal staining and TBUT data are presented below in table 1, with 15S-HETE (Biomol Research Laboratories, Plymouth Meeting, Pa.) treatment of ConA-injected eyes used as a positive control.
  • Compound 1 was evaluated for its ability to suppress neutrophil influx into the rat eye in a model of endotoxin-induced uveitis.
  • the compound was prepared at concentrations of 0.01%, 0.1%, 1.0% w/v in an ophthalmic suspension vehicle, and dexamethasone (Sigma-Aldrich Company, St. Louis, Mo.) formulated in the same vehicle served as reference compound.
  • Uveitis was induced by subplantar injection of endotoxin (200 ⁇ g in 0.1 mL saline) in the right hind paw of female Lewis rats (5/group).
  • Test compound of vehicle (5 ⁇ L) was administered topically to each eye of the experimental animals at the time of endoxtoxin injection and again 4 hours later.
  • a compound of formula I is administered in a pharmaceutically acceptable carrier for topical ophthalmic administration.
  • the compositions are formulated in accordance with methods known in the art.
  • the compositions may contain more than one compound of formula I. Additionally, the compositions may contain a second drug, other than a compound of formula I.
  • compositions of the present invention contain a pharmaceutically effective amount of a compound of formula I.
  • a pharmaceutically effective amount means an amount sufficient to reduce or eliminate uveitis or dry eye symptoms.
  • the compositions of the present invention will contain from 0.00001 to 0.01% of a compound of formula I for treating dry eye, and from 0.01% to 3% of a compound of formula 1 for treating uveitis.
  • the compositions of the present invention will contain from 0.00003 to 0.001% of a compound of formula I for treating dry eye, and from 0.1% to 1% of a compound of formula 1 for treating uveitis.
  • compositions administered according to the present invention may also include various other ingredients, including but not limited to surfactants, tonicity agents, buffers, preservatives, co-solvents and viscosity building agents.
  • tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions.
  • sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity.
  • Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm).
  • An appropriate buffer system e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid
  • the particular concentration will vary, depending on the agent employed.
  • the buffer will be chosen to maintain a target pH within the range of pH 5.5-8.
  • compositions of the present invention are known in the art and may be included in the compositions of the present invention.
  • Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941, carbomer 940, carbomer 974P.
  • monomeric polyols such as, glycerol, propylene glycol, ethylene glycol
  • polymeric polyols such as, polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), dex
  • Topical ophthalmic products are typically packaged in multidose form.
  • Preservatives are typically required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art.
  • Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v.
  • Unit dose compositions of the present invention will be sterile, but typically will not contain a preservative and will be unpreserved.
  • 1-2 drops of such compositions will be administered from once to many times per day.
  • Example 7 for treating dry eye
  • Example 8 for treating uveitis.

Abstract

The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.

Description

  • This application is a continuation-in-part of U.S. Ser. No. 11/127,895 filed May 12, 2005, which claims priority to U.S. Provisional Application U.S. Ser. No. 60/571,162 filed May 14, 2004.
  • The present invention is directed to the treatment of dry eye disorders. In particular, the present invention is directed toward the use of 5,6,7-trihydroxyheptanoic acid and its analogs to treat dry eye and uveitis in mammals.
  • BACKGROUND OF THE INVENTION
  • Dry eye, also known generically as keratoconjunctivitis sicca, is a common ophthalmological disorder affecting millions of Americans each year. The condition is particularly widespread among post-menopausal women due to hormonal changes following the cessation of fertility. Dry eye may afflict an individual with varying severity. In mild cases, a patient may experience burning, a feeling of dryness, and persistent irritation such as is often caused by small bodies lodging between the eye lid and the eye surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's disease and cicatricial pemphigoid manifest dry eye complications.
  • Although it appears that dry eye may result from a number of unrelated pathogenic causes, all presentations of the complication share a common effect, that is the breakdown of the pre-ocular tear film, which results in dehydration of the exposed outer surface and many of the symptoms outlined above (Lemp, Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes, The CLAO Journal, volume 21, number 4, pages 221-231 (1995)).
  • Practitioners have taken several approaches to the treatment of dry eye. One common approach has been to supplement and stabilize the ocular tear film using so-called artificial tears instilled throughout the day. Other approaches include the use of ocular inserts that provide a tear substitute or stimulation of endogenous tear production.
  • Examples of the tear substitution approach include the use of buffered, isotonic saline solutions, aqueous solutions containing water soluble polymers that render the solutions more viscous and thus less easily shed by the eye. Tear reconstitution is also attempted by providing one or more components of the tear film such as phospholipids and oils. Phospholipid compositions have been shown to be useful in treating dry eye; see, e.g., McCulley and Shine, Tear film structure and dry eye, Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998). Examples of phospholipid compositions for the treatment of dry eye are disclosed in U.S. Pat. Nos. 4,131,651 (Shah et al.), 4,370,325 (Packman), 4,409,205 (Shively), 4,744,980 and 4,883,658 (Holly), 4,914,088 (Glonek), 5,075,104 (Gressel et al.), 5,278,151 (Korb et al.), 5,294,607 (Glonek et al.), 5,371,108 (Korb et al.) and 5,578,586 (Glonek et al.). U.S. Pat. No. 5,174,988 (Mautone et al.) discloses phospholipid drug delivery systems involving phospholipids, propellants and an active substance.
  • Another approach involves the provision of lubricating substances in lieu of artificial tears. For example, U.S. Pat. No. 4,818,537 (Guo) discloses the use of a lubricating, liposome-based composition, and U.S. Pat. No. 5,800,807 (Hu et al.) discloses compositions containing glycerin and propylene glycol for treating dry eye.
  • Although these approaches have met with some success, problems in the treatment of dry eye nevertheless remain. The use of tear substitutes, while temporarily effective, generally requires repeated application over the course of a patient's waking hours. It is not uncommon for a patient to have to apply artificial tear solution ten to twenty times over the course of the day. Such an undertaking is not only cumbersome and time consuming, but is also potentially very expensive. Transient symptoms of dry eye associated with refractive surgery have been reported to last in some cases from six weeks to six months or more following surgery.
  • Aside from efforts directed primarily to the alleviation of symptoms associated with dry eye, methods and compositions directed to treatment of the dry eye condition have also been pursued. For example, U.S. Pat. No. 5,041,434 (Lubkin) discloses the use of sex steroids, such as conjugated estrogens, to treat dry eye conditions in post-menopausal women; U.S. Pat. No. 5,290,572 (MacKeen) discloses the use of finely divided calcium ion compositions to stimulate pre-ocular tear film production; and U.S. Pat. No. 4,966,773 (Gressel et al.) discloses the use of microfine particles of one or more retinoids for ocular tissue normalization.
  • Some recent literature reports suggest that patients suffering from dry eye syndrome disproportionately exhibit the hallmarks of excessive inflammation in relevant ocular tissues, such as the lacrimal and meibomian glands. The use of various compounds to treat dry eye patients, such as steroids [e.g. U.S. Pat. No. 5,958,912; Marsh, et al., Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome, Ophthalmology, 106(4): 811-816 (1999); Pflugfelder, et. al. U.S. Pat. No. 6,153,607], cytokine release inhibitors (Yanni, J. M.; et. al. WO 0003705 A1), cyclosporine A [Tauber, J. Adv. Exp. Med. Biol. 1998, 438 (Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2), 969], and 15-HETE (Yanni et. al., U.S. Pat. No. 5,696,166), has been disclosed.
  • Uveitis is an intraocular inflammatory condition that is usually limited to the anterior ocular structures, and can be managed with topical corticosteroids. The inflammatory process can extend behind the lens to affect the pars plana, the vitreous cavity, the choroid, and the retina. These intermediate and posterior manifestations are relatively rare but contribute disproportionately to visual morbidity and present serious therapeutic difficulties. Systemic corticosteroids constitute the first line of treatment for most sight-threatening uveitides. Their long term use is limited by universal and debilitating adverse effects. Second-line agents that allow a reduction in steroid use, such as cyclosporin and azathioprine, offer alternative approaches. Unfortunately their use is frequently limited by a narrow therapeutic window and significant adverse side effects.
  • Lee et. al. have disclosed that compounds 1 and 2 inhibit LTB4-induced chemotaxis of neutrophils as potently as lipoxin A4 [Lee et. al., Biochemical and Biophysical Research Communications 1991, 180(3), 1416-21]. Lipoxin A4 and certain analogs thereof have been reported to be anti-inflammatory agents (see for example Serhan et. aL, U.S. Pat. No. 5,441,951). Certain lipoxin analogs have been claimed for treating dry eye (Gamache et. al., U.S. Pat. No. 6,645,978 B1). However to the best of our knowledge no compounds of the present invention have been described for treating dry eye or uveitis.
  • Figure US20110130451A1-20110602-C00001
  • SUMMARY OF THE INVENTION
  • The present invention is directed to methods for the treatment of dry eye and uveitis. According to the methods of the present invention, a 5,6,7-trihydroxyheptanoic acid or analog is administered to a patient. The 5,6,7-trihydroxyheptanoic acid or analog is preferably administered in an ophthalmic composition dosed topically to a patient's eye.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Unless indicated otherwise, all component amounts are presented on a % (w/v) basis.
  • According to the methods of the present invention, a composition comprising a compound of formula I is topically administered to a mammal in need thereof:
  • Figure US20110130451A1-20110602-C00002
  • wherein
    • R1 is C2H5, CO2R, CONR2R3, CH2OR4, or CH2NR5R6, where:
      • R is H, C1-6 straight chain or branched alkyl, C3-6 cycloalkyl, or phenyl, or R1 is a carboxylate salt of formula CO2 R+, where R+ is Li+, Na+, K+, or an ammonium moiety of formula +NR10R11R12R13;
      • R2, R3 are independently H, C1-6 alkyl, C3-6 cycloalkyl, benzyl, phenyl, OH, OCH3, or OC2H5, provided that at most only one of R2, R3 is OH, OCH3, or OC2H5;
      • R4 is H, C(O)R14, C1-6 alkyl, C3-6 cycloalkyl, benzyl, or phenyl;
      • R5, R6 are independently H, C(O)R14, C1-6 alkyl, C3-6 cycloalkyl, benzyl, phenyl, OH, OCH3, or OC2H5, provided that at most only one of R2, R3 is OH, OCH3, or OC2H5;
      • R7, R8, and R9 are independently H, CH3, C2H5, C(O)R14, or CO2R15;
      • or R7 and R8 or R8 and R9 together constitute a carbonyl group (C═O), thus forming a cyclic carbonate;
      • or OR8R1 together form a cyclic ester (a lactone);
      • R10—R1 are independently H or C1-6 alkyl, each alkyl group optionally bearing an OH or OCH3 substituent;
      • R14 is H, C1-6 alkyl, C3-6 cycloalkyl, benzyl, or phenyl;
      • R15 is C1-6 alkyl, C3-6 cycloalkyl, benzyl, or phenyl; and
        Figure US20110130451A1-20110602-P00001
        indicates that the OR9 substituent can be arranged to afford the R or S absolute configuration:
  • Figure US20110130451A1-20110602-C00003
    • Preferred compounds of formula I are those wherein:
      • R1 is C2H5, CO2R, CH2OR4, or a carboxylate salt of formula CO2 R+;
      • R+ is Li+, Na+, K+, or NH4 +;
      • R is H, CH3, C2H5, n-C3H7, or i-C3H7;
      • R4 is H, COCH3, or CH3; and
      • R7, R8, R9 are independently H, CH3, CH3CO;
      • or R7 and R8 or R8 and R9 together constitute a carbonyl group (C═O), thus forming a cyclic carbonate;
      • or OR8R1 together form a cyclic ester (a lactone).
  • Among the especially preferred compounds are compounds 1-6. Compound 1 is commercially available from Biomol Research Laboratories, Plymouth Meeting, Pa., and compound 2 can be prepared as detailed in Lee et. al., Biochemical and Biophysical Research Communications 1991, 180(3), 1416-21. Compounds 3-6 can be prepared as described in examples 1-4 below.
  • Figure US20110130451A1-20110602-C00004
  • EXAMPLE 1 Synthesis of Compound 3
  • Figure US20110130451A1-20110602-C00005
  • A solution of methyl ester 1 (20 mg, 0.104 mmol) in MeOH (2.1 mL) containing 1 M LiOH (0.5 mL, 0.5 mmol) was heated in a microwave heater at 120° C. for 6 minutes. The reaction was concentrated and the residue was chromatographed on a 10 mm diameter×18 cm tall C18 reverse-phase silica gel column eluting with 7:3 v:v 0.05 M HCl:acetonitrile to afford a crude white solid after concentration (40.9 mg). The solid was rinsed with hot CH3CN (2×2 mL) and the filtrate was concentrated to afford lactone 3 (7.8 mg, 47%). 13C NMR (150 MHz, dmso-d6) δ 171.12 (C), 79.86 (CH), 72.44 (CH), 62.03 (CH2), 29.39 (CH2), 21.67 (CH2), 17.55 (CH2).
  • EXAMPLE 2 Synthesis of Compound 4
  • Figure US20110130451A1-20110602-C00006
  • A solution of methyl ester 1 in aqueous MeOH is heated to reflux in the presence of 3 equivalents of lithium hydroxide. After 6 h the reaction is cooled to room temperature and the pH of the solution is adjusted to 6 by the addition of 70-9 mesh sulfonic acid resin MP (commercially available from Novabiochem/EMD Biosciences, 10394 Pacific Center Court, San Diego, Calif. 92121). The solution is filtered through a 0.2 μM poly-terfluoroethylene syringe filter and concentrated to afford the lithium carboxylate 4 as a white solid. 1H NMR (D2O, 400 MHz) δ 3.69-3.64 (m, 1H), 3.55-3.47 (m, 3H), 2.16-2.12 (m, 2H), 1.67-1.64 (m, 1H), 1.54-1.48 (m, 2H), 1.38-1.34 (m, 1H). 13C NMR (D2O, 100 MHz) δ 183.46 (C), 74.61 (CH), 71.67 (CH), 62.49 (CH2), 37.26 (CH2), 31.55 (CH2), 22.04 (CH2).
  • EXAMPLE 3 Synthesis of Compound 5
  • Figure US20110130451A1-20110602-C00007
  • A solution of lactone 3 in THF is treated with 3 to 5 equivalents of an ethanolic solution of sodium ethoxide. After 10 h the reaction is quenched by the addition of saturated aqueous potassiuni dihydrogen phosphate until the pH is about 6. The solution is extracted with ethyl acetate, the organic layer is dried over MgSO4, filtered, and concentrated, and the residue is chromatographed on a silica gel column to afford ethyl ester 5.
  • EXAMPLE 4 Synthesis of Compound 6
  • Figure US20110130451A1-20110602-C00008
  • A solution of lactone 3 in THF is treated with 3 to 5 equivalents of an sodium isopropoxide in isopropanol. After 10 h the reaction is quenched by the addition of saturated aqueous potassium dihydrogen phoiphate until the pH is about 6. The solution is extracted with ethyl acetate, the organic layer is dried over MgSO4, filtered, and concentrated, and the residue is chromatographed on a silica gel column to afford isopropyl ester 6.
  • EXAMPLE 5 Protective Effect of Compound 1 in a Rabbit Model of Dry Eye
  • Compound 1 was evaluated in a rabbit model of dry eye. New Zealand white rabbits (approximately 2.5 kg; obtained from Myrtle's Rabbitry, Thompson Station, Tenn.) were randomized and dosed topically twice a day with either 50 μl of compound 1 formulated in 0.064%/BSS® at concentrations of 1, 10 , or 100 μM , or with 0.064%/BSS® vehicle. After 24 h the rabbits were anesthetized by subcutaneous administration of ketamine hydrochloride (30 mg/kg) and xylazine (6 mg/kg) and each rabbit received bilateral injections of Conconavilin A (ConA) (300 μg/30 μl) or saline (30 μl). Desiccation was initiated one day following lacrimal gland injection by placing conscious animals in an environmental chamber (20-30% humidity, 75° C.). Following 72 hours of exposure to environment, the animals were assessed for corneal staining upon exposure of the cornea to the dye methylene blue; less staining indicates less damage to the cornea. The rabbits were anesthetized by subcutaneous administration of ketamine hydrochloride (30 mg/kg) and xylazine (6 mg/kg). Sutures were placed in each upper and lower eyelid and lifted to form a corneal/conjunctival cup. Methylene blue dye (1 mL, 1% in distilled water) was added to the cup for five minutes and the excess removed by washing with 200 mL of BSS®. The contralateral eye was then stained using the same procedure. Rabbits were euthanized immediately following the staining procedure and the eyes were excised. The corneas were isolated and a 9.5 mm punch of the cornea was placed overnight in 2 mL of acetone/saturated sodiuim sulfate (7:3 v/v). The concentration of the extracted dye was determined spectrophotometrically by measuring its absorbance at λ=660 nanometers (A660). Percent inhibition was calculated as {1-[(A660test item-A660Normal)/(A660BSS-A660Normal)]}×100, where A660test item is the absorbance of dye from ConA-injected eyes dosed with compound 1, A660Normal is the absorbance of dye from saline-injected eyes, and A660BSS is the absorbance of dye in ConA-injected eyes dosed with 0.064% ethanol/BSS® solution vehicle. A higher percent inhibition of staining indicates more protection of the cornea from damage.
  • A second group of animals was evaluated for tear film quality by measuring each animal's tear breakup time (TBUT). Using the same experimental protocol as above for inducing rabbit ocular damage, TBUT was determined daily by instilling 5 μL of sodium fluorescein into the cul de sac and manually blinking the lids to distribute the fluroescein within the tear film. Under slit lamp observation, the eye was held open and the time whereby one or more black spots or streaks appeared in the precorneal tear film was recorded. The rabbits were euthanized 3 days following ConA injection. Larger TBUT values indicate better tear film quality and more protection from ocular damage. TBUT data is expressed as % of baseline, with baseline TBUT being that observed for saline-injected, vehicle-treated eyes.
  • The % inhibition of corneal staining and TBUT data are presented below in table 1, with 15S-HETE (Biomol Research Laboratories, Plymouth Meeting, Pa.) treatment of ConA-injected eyes used as a positive control.
  • TABLE 1
    Effect of Compound 1 on Ocular Damage in Rabbits Induced by
    Lacrimal Gland ConA Injection Followed by Desiccation
    % Inhibition
    of Corneal
    Concentration Staining, ± TBUT, % of
    Compound (μM) S.D.a Baseline, ± S.D.
    15S-HETE   1 77 ± 18b   54 ± 21b
    1   1 75 ± 12b   67 ± 17b
    1  10 54 ± 9b,c   45 ± 17b
    1 100 38 ± 34b,c 51 ± 18b
    aS.D. = Standard Deviation.
    bp < 0.01 (Dunnett's t-test) compared to vehicle.
    cp < 0.01 (Dunnett's t-test) compared to 15S-HETE.
  • EXAMPLE 6 Protective Effect of Compound 1 in a Rat Model of Uveitis
  • Compound 1 was evaluated for its ability to suppress neutrophil influx into the rat eye in a model of endotoxin-induced uveitis. The compound was prepared at concentrations of 0.01%, 0.1%, 1.0% w/v in an ophthalmic suspension vehicle, and dexamethasone (Sigma-Aldrich Company, St. Louis, Mo.) formulated in the same vehicle served as reference compound. Uveitis was induced by subplantar injection of endotoxin (200 μg in 0.1 mL saline) in the right hind paw of female Lewis rats (5/group). Test compound of vehicle (5 μL) was administered topically to each eye of the experimental animals at the time of endoxtoxin injection and again 4 hours later. Twenty four hours post endotoxin injection, animals were sacrificed by CO2 inhalation, and total ocular neutrophil (PMN) content was assesed indirectly by determination of myeloperoxidase activity. Ocular PMN content in each group was then compared with that observed in the vehicle-treated group using Dunnet's t-test. The results are shown below in table 2.
  • TABLE 2
    Effect of Compound 1 on Endotoxin-Induced Uveitis in Rats
    Following Topical Ocular Administration
    Myeloperoxidase
    (μM/min/100 mg)
    Concentration (x ± standard %
    Compound (%, w/v) deviation) inhibition
    Carbopol Vehicle 164 ± 46 
    1 0.01 143 ± 64  13
    0.1  161 ± 37   2
    1.0  97 ± 35  41*
    Dexamethasone 0.1  15 ± 7   91*
    *p < 0.01, Dunnett's t-test.
  • According to the methods of the present invention, a compound of formula I is administered in a pharmaceutically acceptable carrier for topical ophthalmic administration. The compositions are formulated in accordance with methods known in the art. The compositions may contain more than one compound of formula I. Additionally, the compositions may contain a second drug, other than a compound of formula I.
  • The compositions of the present invention contain a pharmaceutically effective amount of a compound of formula I. As used herein, “a pharmaceutically effective amount” means an amount sufficient to reduce or eliminate uveitis or dry eye symptoms. Generally, the compositions of the present invention will contain from 0.00001 to 0.01% of a compound of formula I for treating dry eye, and from 0.01% to 3% of a compound of formula 1 for treating uveitis. Preferably, the compositions of the present invention will contain from 0.00003 to 0.001% of a compound of formula I for treating dry eye, and from 0.1% to 1% of a compound of formula 1 for treating uveitis.
  • The compositions administered according to the present invention may also include various other ingredients, including but not limited to surfactants, tonicity agents, buffers, preservatives, co-solvents and viscosity building agents.
  • Various tonicity agents may be employed to adjust the tonicity of the composition, preferably to that of natural tears for ophthalmic compositions. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, dextrose and/or mannitol may be added to the composition to approximate physiological tonicity. Such an amount of tonicity agent will vary, depending on the particular agent to be added. In general, however, the compositions will have a tonicity agent in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm).
  • An appropriate buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate or boric acid) may be added to the compositions to prevent pH drift under storage conditions. The particular concentration will vary, depending on the agent employed. Preferably, however, the buffer will be chosen to maintain a target pH within the range of pH 5.5-8.
  • Other compourids designed to lubricate, “wet,” approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of dry eye symptoms and conditions upon ocular administration to the eye are known in the art and may be included in the compositions of the present invention. Such compounds may enhance the viscosity of the composition, and include, but are not limited to: monomeric polyols, such as, glycerol, propylene glycol, ethylene glycol; polymeric polyols, such as, polyethylene glycol, hydroxypropylmethyl cellulose (“HPMC”), carboxy methylcellulose sodium, hydroxy propylcellulose (“HPC”), dextrans, such as, dextran 70; water soluble proteins, such as gelatin; and vinyl polymers, such as, polyvinyl alcohol, polyvinylpyrrolidone, povidone and carbomers, such as, carbomer 934P, carbomer 941, carbomer 940, carbomer 974P.
  • Topical ophthalmic products are typically packaged in multidose form. Preservatives are typically required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0% w/v. Unit dose compositions of the present invention will be sterile, but typically will not contain a preservative and will be unpreserved.
  • Generally, 1-2 drops of such compositions will be administered from once to many times per day.
  • Representative eye drop formulations are provided below in Example 7 for treating dry eye and in Example 8 for treating uveitis.
  • EXAMPLE 7
  • Ingredient Concentration (% w/v)
    Compound of formula I 0.00003-0.001  
    Ethanol 0.03-0.2 
    Boric Acid 0.1-0.3
    Polyoxyl 40 Stearate 0.1  
    Edetate Disodium 0.01 
    Polyquaternium 1 0.001
    NaOH/HCl q.s. to pH 6-8
    Purified Water q.s. to 100%
  • EXAMPLE 8
  • Ingredient Concentration (% w/v)
    Compound of formula I 0.1-1.0
    Hydroxypropyl methylcellulose 0.1-0.5
    Dextran 70 0.1  
    Sodium Chloride 0.8  
    Potassium Chloride 0.12 
    Dibasic Sodium Phosphate 0.025
    Edetate Disodium 0.01 
    Polyquaternium-1 0.001-0.005
    NaOH/HCl q.s. to pH 6-8
    Purified Water q.s. to 100
  • This invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its special or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims (12)

1. (canceled)
2. A method for the treatment of dry eye or uveitis in a mammal, which comprises topically administering to the eye of the mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula I:
Figure US20110130451A1-20110602-C00009
wherein
R1 is C2H5, CO2R, CH2OR4, or a carboxylate salt of formula CO2 R+;
R+ is Li+, Na+, K+, or NH4 +;
R is H, CH3, C2H5, n-C3H7, or i-C3H7; and
R4 is H, COCH3, or CH3; and
R7, R8, R9 are independently H, CH3, CH3CO;
or R7 and R8 or R8 and R9 together constitute a carbonyl group (C═O), thus forming a cyclic carbonate; provided that if R7═R8═R9═H, then R1═CH2OR4-;
or OR8R1 together form a lactone.
3. (canceled)
4. (canceled)
5. The method of claim 2, wherein a compound of formula I is used to treat uveitis.
6. The method of claim 2, wherein a compound of formula I is used to treat dry eye.
7. (canceled)
8. (canceled)
9. The method of claim 5, wherein the pharmaceutically acceptable amount is from 0.1 to 1% (w/v).
10. The method of claim 6 wherein the pharmaceutically acceptable amount is from 0.00003 to 0.001% (w/v).
11. The method of claim 9, wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; and viscosity building agents.
12. The method of claim 10, wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; and viscosity building agents.
US13/022,692 2004-05-14 2011-02-08 Method of treating dry eye disorders and uveitis Abandoned US20110130451A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/022,692 US20110130451A1 (en) 2004-05-14 2011-02-08 Method of treating dry eye disorders and uveitis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57116204P 2004-05-14 2004-05-14
US11/127,895 US20050256189A1 (en) 2004-05-14 2005-05-12 Method of treating dry eye disorders and uveitis
US11/268,301 US7923471B2 (en) 2004-05-14 2005-11-07 Method of treating dry eye disorders and uveitis
US13/022,692 US20110130451A1 (en) 2004-05-14 2011-02-08 Method of treating dry eye disorders and uveitis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/268,301 Continuation US7923471B2 (en) 2004-05-14 2005-11-07 Method of treating dry eye disorders and uveitis

Publications (1)

Publication Number Publication Date
US20110130451A1 true US20110130451A1 (en) 2011-06-02

Family

ID=46123936

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/268,301 Expired - Fee Related US7923471B2 (en) 2004-05-14 2005-11-07 Method of treating dry eye disorders and uveitis
US13/022,692 Abandoned US20110130451A1 (en) 2004-05-14 2011-02-08 Method of treating dry eye disorders and uveitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/268,301 Expired - Fee Related US7923471B2 (en) 2004-05-14 2005-11-07 Method of treating dry eye disorders and uveitis

Country Status (1)

Country Link
US (2) US7923471B2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
US7687539B1 (en) 2005-11-07 2010-03-30 Alcon Research, Ltd. Method of treating ocular allergy
CA2788333A1 (en) * 2010-02-25 2011-09-01 Alcon Research, Ltd. Method of accelerating corneal wound healing
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
KR102236356B1 (en) 2017-11-24 2021-04-05 주식회사 종근당 Compositions for Preventing or Treating Lupus
KR20190099952A (en) * 2018-02-20 2019-08-28 주식회사 종근당 Compositions for Preventing or Treating Uveitis

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4883658A (en) * 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5294607A (en) * 1990-05-29 1994-03-15 Ocular Research Of Boston, Inc. Dry eye treatment process and solution
US5371108A (en) * 1991-10-02 1994-12-06 Ocular Research Of Boston, Inc. Dry eye treatment process and solution
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US5578586A (en) * 1987-04-02 1996-11-26 Ocular Research Of Boston, Inc. Dry eye treatment process and solution
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5800607A (en) * 1995-07-06 1998-09-01 Hoechst Aktiengesellschaft Process for the preparation of liquid pigment preparations
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US6153607A (en) * 1995-12-04 2000-11-28 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
US6645978B1 (en) * 1999-11-09 2003-11-11 Alcon, Inc. Lipoxin A4 and its analogs for the treatment of dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109970T1 (en) * 1987-09-03 1994-09-15 Univ Georgia Res Found CYCLOSPORIN EYE REMEDY.
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
CA2306393C (en) 1998-07-14 2008-12-23 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131651A (en) * 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) * 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) * 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) * 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5578586A (en) * 1987-04-02 1996-11-26 Ocular Research Of Boston, Inc. Dry eye treatment process and solution
US5075104A (en) * 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5294607A (en) * 1990-05-29 1994-03-15 Ocular Research Of Boston, Inc. Dry eye treatment process and solution
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5371108A (en) * 1991-10-02 1994-12-06 Ocular Research Of Boston, Inc. Dry eye treatment process and solution
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US5800607A (en) * 1995-07-06 1998-09-01 Hoechst Aktiengesellschaft Process for the preparation of liquid pigment preparations
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US6153607A (en) * 1995-12-04 2000-11-28 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance (or turnover)
US6645978B1 (en) * 1999-11-09 2003-11-11 Alcon, Inc. Lipoxin A4 and its analogs for the treatment of dry eye

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chang et al (Pharmacol Rev 58:463-487, 2006). *

Also Published As

Publication number Publication date
US20060058375A1 (en) 2006-03-16
US7923471B2 (en) 2011-04-12

Similar Documents

Publication Publication Date Title
EP2175858B1 (en) Pharmaceutical compositions and methods of treating dry eye disorders
US20110130451A1 (en) Method of treating dry eye disorders and uveitis
EP1744736B1 (en) Method of treating dry eye disorders and uveitis
US20060069075A1 (en) Methods for treating dry eye
US20050182039A1 (en) Use of Loteprednol etabonate for the treatment of dry eye
US6872382B1 (en) Use of selective PDE IV inhibitors to treat dry eye disorders
DE60218153T2 (en) USE OF PROTEASOME INHIBITORS FOR THE TREATMENT OF DRY EYES
US20020009507A1 (en) Use of polyethoxylated castor oil for the treatment of dry eye
DE60120990T2 (en) USE OF 3-BEZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF NETWORK DISEASES
US6645994B1 (en) Method of treating dry eye disorders
US7745461B1 (en) Method of treating dry eye disorders
US20030109508A1 (en) Methods for treating dry eye
US20080070958A1 (en) Therapeutic Agent for Keratoconjunctival Disorder
US7235556B2 (en) Methods of treating dry eye disorders
US20030109488A1 (en) Methods for treating dry eye
US7112588B2 (en) Use of proteasome inhibitors to treat dry eye disorders
US6696453B2 (en) Use of NF-κB inhibitors to treat dry eye disorders
ZA200308770B (en) Method of treating dry eye disorders.
JP2004175749A (en) Therapeutic agent for dry eye and disease accompanied by dry eye

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: MERGER;ASSIGNOR:ALCON, INC.;REEL/FRAME:026376/0076

Effective date: 20110408

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION